Dr. Reddy's Laboratories
Nomura’s Saion Mukherjee picks Dr Reddy’s as top pharma bet amid semaglutide opportunitySaion Mukherjee, Managing Director & Head of Equity Research at Nomura highlights Dr Reddy’s as his top pick in the sector amidst large firms like Sun Pharma, Lupin and Zydus - all preparing to tap the opportunity as semaglutide goes off patent Lenacapavir A long-acting, USFDA-approved treatment for HIV-1 infection. Our work with Lenacapavir supports our goal to expand HIV treatment and prevention, especially
Basic Information
- Category: Healthcare
- Founded: 1984
- Headquarters: Hyderabad, India
- Website: https://www.drreddys.com
Documented Facts
- Founded: 1984 (No linked source recorded for this statement.)
- Headquarters: Hyderabad, India (No linked source recorded for this statement.)
- Category: Healthcare (No linked source recorded for this statement.)
- Email: shares@drreddys.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: K7 (No linked source recorded for this statement.)
- Stock ticker: RDY (NYSE) (No linked source recorded for this statement.)
Products and Services
- Dr. Reddy's Laboratories Products: Indian multinational pharmaceutical company.
Evidence and Sources
- Official Website (Primary Source)
- DR REDDYS LABORATORIES LTD — SEC EDGAR (reference)
Citation Guidance
Explore Healthcare profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Dr. Reddy's Laboratories.
- Canonical profile: https://brandsource.ai/brands/dr-reddy-s-laboratories
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/dr-reddy-s-laboratories/json-ld
- Citation profile API: https://brandsource.ai/api/brands/dr-reddy-s-laboratories/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (82/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-01
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Nomura’s Saion Mukherjee picks Dr Reddy’s as top pharma bet amid semaglutide opportunitySaion Mukherjee, Managing Director & Head of Equity Research at Nomura highlights Dr Reddy’s as his top pick in the sector amidst large firms like Sun Pharma, Lupin and Zydus - all preparing to tap the opportunity as semaglutide goes off patent Lenacapavir A long-acting, USFDA-approved treatment for HIV-1 infection. Our work with Lenacapavir supports our goal to expand HIV treatment and prevention, especially
Available profile information
- Official website is captured for entity disambiguation.
- 2 supporting sources linked.
- 7 structured facts available for extraction.
- 1 product or service signal captured.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.